• Building a CAR-T Bridge With Bispecifics for Lymphoma

    By Gina ShawBispecific antibodies (BiAbs) are achieving impressive results, in some cases more than doubling the survival gains seen with conventional chemotherapy. These advances are pushing oncology teams to reconsider whether these powerful anticancer drugs can be used earlier to carry more patients to potentially curative cellular therapy, speakers noted during a session at HOPA26, in New Orleans.Glofitamab-gxbm (Columvi, Genentech) is a case in point. When added to gemcitabine and oxaliplat

Follow @newsl_pharmacy on Twitter!